drugset / Trial / NCT00352092

Pilot Study for HLA Identical Living Donor Renal Transplant Recipients

NCT00352092

Phase 4 Completed 20 enrolled University of Cincinnati Roche Pharma AG · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of a steroid-free and calcineurin-inhibitor free treatment regimen for patients who are receiving a kidney transplant from a living donor that is HLA-identical (has a similar immune system).

Timeline

Start
2002-06
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule
Subject Sirolimus Small molecule
Subject Tacrolimus Small molecule

Indications

No indication recorded.